688180 Stoklara Genel Bakış Bir biyofarmasötik şirketi olan Shanghai Junshi Biosciences Co, Ltd, Çin Halk Cumhuriyeti'nde kötü huylu tümörler, nörolojik, otoimmün, kronik metabolik, sinir sistemi ve bulaşıcı hastalıkların tedavi alanlarında çeşitli ilaçların keşfi, geliştirilmesi ve ticarileştirilmesi ile uğraşmaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Shanghai Junshi Biosciences Co., Ltd. Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Shanghai Junshi Biosciences Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı HK$27.33 52 Haftanın En Yüksek Seviyesi HK$42.60 52 Haftanın En Düşük Seviyesi HK$23.08 Beta 0.41 1 Aylık Değişim -12.35% 3 Aylık Değişim -14.03% 1 Yıllık Değişim -33.75% 3 Yıllık Değişim -54.68% 5 Yıllık Değişim n/a Halka arzdan bu yana değişim -81.90%
Son Haberler & Güncellemeler
Shanghai Junshi Biosciences Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025 Dec 27
Shanghai Junshi Biosciences Co., Ltd. Announces Board and Committee Changes Dec 20 Shanghai Junshi Biosciences Co., Ltd.(SHSE:688180) dropped from Shanghai Stock Exchange 180 Value Index
Shanghai Junshi Biosciences Co., Ltd. Announces Change of Address of Principal Place of Business in Hong Kong Nov 30 Shanghai Junshi Biosciences Co., Ltd. Announces Change of Address of Principal Place of Business in Hong Kong
Shanghai Junshi Biosciences Co., Ltd. Announces the Approval of New Drug Application for Ongericimab Injection Oct 14 Daha fazla güncelleme görün
Shanghai Junshi Biosciences Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025 Dec 27
Shanghai Junshi Biosciences Co., Ltd. Announces Board and Committee Changes Dec 20 Shanghai Junshi Biosciences Co., Ltd.(SHSE:688180) dropped from Shanghai Stock Exchange 180 Value Index
Shanghai Junshi Biosciences Co., Ltd. Announces Change of Address of Principal Place of Business in Hong Kong Nov 30 Shanghai Junshi Biosciences Co., Ltd. Announces Change of Address of Principal Place of Business in Hong Kong
Shanghai Junshi Biosciences Co., Ltd. Announces the Approval of New Drug Application for Ongericimab Injection Oct 14
Shanghai Junshi Biosciences Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Sep 30
Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial Sep 26
Shanghai Junshi Biosciences Co., Ltd. Receives Approval by the European Commission for Marketing of Toripalimab Sep 24
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma Aug 13
Shanghai Junshi Biosciences Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug Application for WJ47156 Tablets Jul 09
Shanghai Junshi Biosciences Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024 Jun 28
Shanghai Junshi Biosciences Co., Ltd. Receives the Drug Registration Certificate Issued by the National Medical Products Administration Jun 26
Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes Jun 24
Shanghai Junshi Biosciences Co., Ltd Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer Jun 19
Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration Jun 14
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma Jun 13
Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 21, 2024 May 31 Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer Apr 10
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection Apr 03
Shanghai Junshi Biosciences Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Mar 30
Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023 Feb 01
Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer Jan 13 Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board
Shanghai Junshi Biosciences Co., Ltd. Announces Publication of Results from Toripalimab, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine Jan 10
Shanghai Junshi Biosciences Co., Ltd. Announces New Indications of TUOYI and MINDEWEI Included in New Edition of National Reimbursement Drug List Dec 13 Shanghai Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia's TGA
Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association Nov 29
Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma Oct 28
Shanghai Junshi Biosciences Co., Ltd. Directors Appointments Oct 21
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab for the First-Line Treatment of Melanoma Met Primary Endpoint Sep 26
Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares. Sep 13
Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares. Sep 12 Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Notice of Approval for Clinical Trial
Shanghai Junshi Biosciences Co., Ltd. Announces Resignation of Wu Hai as Non-Executive Director Aug 31
Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares. Aug 28
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-Linetreatment of Advanced RCC Jul 12
Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes Jul 01
Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Acceptance Notice For the Investigational New Drug Application Jun 20 Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 30, 2023
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple - Negative Breast Cancer May 24
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Chemotherapy for the First-Line Treatment of ES-SCLC Met Primary Endpoint May 08
Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02 Feb 16
Shanghai Junshi Biosciences Co., Ltd. Announces JS401 Injection Receival the Acceptance Notice for The Investigational New Drug Application Feb 01 Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2022 Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of NDA for VV116 in China
Shanghai Junshi Biosciences Co., Ltd, Shanghai Juntop Biosciences Co., Ltd. and Vigonvita Life Sciences Co., Ltd. Announce Progress of the Clinical Studies of VV116 Jan 03
Shanghai Junshi Biosciences Co., Ltd. Receives Acceptance Notice for the Investigational New Drug Application Dec 31
Shanghai Junshi Biosciences Co., Ltd Announces Nejm Publication of Results of Phase 3 Study of Vv116 Versus Paxlovid for Adults At High Risk for Progression to Severe Covid-19 Dec 30
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma Dec 26
Shanghai Junshi Biosciences Co., Ltd. Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting Dec 13
Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes Dec 10
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Marketing Authorization Application of Toripalimab Dec 06
Shanghai Junshi Biosciences Co., Ltd Submits Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency Nov 25
Shanghai Junshi Biosciences Co., Ltd. Announces Receiving the Notice of Approval for Supplemental Drug Application Issued by the National Medical Products Administration Nov 22
Shanghai Junshi Biosciences Co., Ltd. Announces Submission of A Marketing Authorization Application to the European Medicines Agency for Toripalimab Nov 15
Shanghai Junshi Biosciences Co., Ltd. Receives the Notice of Approval for Clinical Trial Issued by the National Medical Products Administration Oct 31
Shanghai Junshi Biosciences Co., Ltd. to Report Nine Months, 2022 Results on Oct 28, 2022 Oct 19
Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology Oct 13
Shanghai Junshi Biosciences Co., Ltd Receives NMPA Approval of sNDA for Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Non-squamous Non-Small Cell Lung Cancer Sep 21 Suzhou Junjing Biomedical Technology Co., Ltd. Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor) Shanghai Junshi Biosciences Co., Ltd. to Report Q2, 2022 Results on Aug 30, 2022
Shanghai Junshi Biosciences Co., Ltd. Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma Jul 22
Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial Issued by National Medical Products Administration Jul 13
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma Jul 07
Shanghai Junshi Biosciences Co., Ltd. and Risen (Suzhou) Pharma Tech Co., Ltd. Announces FDA Approval of Investigational New Drug Application for JS105 Jul 05
Shanghai Junshi Biosciences Co., Ltd. Appoints Zou Jianjun as Executive Director Jun 30 Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 29, 2022
Shanghai Junshi Biosciences Co., Ltd. Announces PAXLOVID Phase III Registrational Trial for Early Treatment of Mild to Moderate Covid-19 May 26 Shanghai Junshi Biosciences Co., Ltd. Announces Vv116 Versus Paxlovid for Early Treatment of Mild to Moderate Covid-19 Reaches Primary Endpoint in Phase Iii Registrational Clinical Study Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with Paclitaxel and Cisplatin in First-Line Treatment of Advanced or Distant Metastatic Esophageal Squamous Cell Carcinoma May 18
Shanghai Junshi Biosciences Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug Application
Shanghai Junshi Biosciences Co., Ltd. Updates on Biologics License Application to the Fdaof Toripalimab for Treatment of Nasopharyngealcarcinoma May 04 Shanghai Junshi Biosciences Co., Ltd. Appoints Zou Jianjun as Deputy General Manager and Global Research and Development President of the Company with Effect from 20 April 2022 Hissedar Getirileri 688180 CN Biotechs CN Pazar 7D -5.7% -0.8% 1.0% 1Y -33.7% -22.3% 8.2%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 688180 geçen yıl % -22.3 oranında getiri sağlayan CN Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: 688180 geçen yıl % 8.2 oranında getiri sağlayan CN Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is 688180's price volatile compared to industry and market? 688180 volatility 688180 Average Weekly Movement 7.3% Biotechs Industry Average Movement 7.9% Market Average Movement 8.1% 10% most volatile stocks in CN Market 12.2% 10% least volatile stocks in CN Market 5.1%
İstikrarlı Hisse Senedi Fiyatı: 688180 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: 688180 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında Bir biyofarmasötik şirketi olan Shanghai Junshi Biosciences Co, Ltd, Çin Halk Cumhuriyeti'nde kötü huylu tümörler, nörolojik, otoimmün, kronik metabolik, sinir sistemi ve bulaşıcı hastalıkların terapötik alanlarında çeşitli ilaçların keşfi, geliştirilmesi ve ticarileştirilmesi ile uğraşmaktadır. Şirket 2012 yılında kurulmuştur ve merkezi Çin Halk Cumhuriyeti'nin Şanghay kentindedir.
Daha fazla göster Shanghai Junshi Biosciences Co., Ltd. Temel Bilgiler Özeti Shanghai Junshi Biosciences'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 688180 temel i̇stati̇sti̇kler Piyasa değeri CN¥23.30b Kazançlar(TTM ) -CN¥1.80b Gelir(TTM ) CN¥1.79b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 688180 gelir tablosu (TTM ) Gelir CN¥1.79b Gelir Maliyeti CN¥622.89m Brüt Kâr CN¥1.16b Diğer Giderler CN¥2.97b Kazançlar -CN¥1.80b
Son Raporlanan Kazançlar
Sep 30, 2024
Sonraki Kazanç Tarihi
Mar 28, 2025
Hisse başına kazanç (EPS) -1.83 Brüt Marj 65.15% Net Kâr Marjı -100.90% Borç/Özkaynak Oranı 43.8%
688180 uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/31 23:26 Gün Sonu Hisse Fiyatı 2024/12/31 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Shanghai Junshi Biosciences Co., Ltd. 19 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Congmin Yuan Citic Securities Co., Ltd. Tan Huan Gan Citic Securities Co., Ltd. Muk Tsz Yung Citigroup Inc
Göster 16 daha fazla analist 
